International study shows wide differences in 5-year survival rates across the globe
the ONA take:
According to a new study published in the journal The Lancet, there are very large differences in 5-year survival among patients with cancer between 67 countries.
For the CONCORD-2 study, researchers used patient data from 279 cancer registries and identified 25.7 million patients with cancer diagnosed with one of the 10 most common cancers, as well as 75,000 children diagnosed with acute lymphoblastic leukemia (ALL) between 1995 and 2009.
Results showed that pediatric patients with ALL had various different 5-year survival rates depending upon what country they reside in. Patients from Indonesia, Jordan, Lesotho, Mongolia, and Tunisia had a 5-year survival rate between 16% and 50%, while patients in Austria, Belgium, Canada, Germany, and Norway had a 5-year survival rate over 90%.
Among the 10 most common cancers, Israel and Ecuador had the highest survival for colon cancer (≥68%); Cyprus, Iceland, and Japan had the highest for rectal cancer (≥70%); and Australia, Brazil, Canada, Cyprus, Israel, Japan, the U.S. and many European countries had the highest survival for breast cancer (≥85%). Mongolia had the lowest survival for breast, colon, and rectal cancers. In Europe, European Russia had the lowest survival for those three cancers.
There are very large differences in 5-year survival among patients with cancer between 67 countries.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|